Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15378006 | 0.99 | USP2 (0.43) | USP2SMN1; SMN2ALDH1A1HSD17B10HPGD | |
| SCHEMBL484745 | 0.92 | ALDH1A1 (0.50) | USP2SMN1; SMN2ALDH1A1HSD17B10ACACB | |
| SCHEMBL484585 | 0.91 | USP2 (0.46) | USP2SMN1; SMN2HPGDACACBGPR119 | |
| Hydrochloric Acid SCHEMBL5322449 | 0.90 | ALDH1A1 (0.49) | USP2SMN1; SMN2ALDH1A1HSD17B10ACACB | |
| Hydrochloric Acid SCHEMBL896891 | 0.90 | USP2 (0.45) | USP2SMN1; SMN2HPGDACACBGPR119 | |
| Oxalic Acid SCHEMBL29782913 | 0.88 | HSD17B10 (0.49) | USP2ALDH1A1HSD17B10ACACBCYP3A4 | |
| SCHEMBL21801899 | 0.87 | HPGD (0.46) | USP2SMN1; SMN2ALDH1A1HPGDEPHX1 | |
| SCHEMBL14801521 | 0.87 | ALDH1A1 (0.42) | USP2SMN1; SMN2ALDH1A1HSD17B10HPGD | |
| SCHEMBL994268 | 0.86 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX1ACACB | |
| SCHEMBL484938 | 0.86 | ALDH1A1 (0.45) | USP2SMN1; SMN2ALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569304-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-03-20 | — | — | EP | claimed |
| WO-2011143148-A1 | SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-17 | — | — | WO | claimed |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025085738-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| CN-119301132-A | Halogenated indole macrocyclic compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118027003-B | PROTAC compound, preparation method thereof and application of PROTAC compound as estrogen receptor degradation agent | 山东大学 | 2024-10-29 | — | — | CN | disclosed |
| CN-118812521-A | Benzo heterocyclic compound and application thereof | 中科中山药物创新研究院 | 2024-10-22 | — | — | CN | disclosed |
| US-20240269298-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-08-15 | — | — | US | disclosed |
| US-20240270739-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | INCYTE CORPORATION | 2024-08-15 | — | — | US | disclosed |
| US-20240254115-A1 | New Pyridine-Sulfonamide Derivatives as Sigma Ligands | ACONDICIONAMIENTO TARRASENSE (ES) | 2024-08-01 | — | — | US | disclosed |
| WO-2011034907-A2 | PROTEIN KINASE CONJUGATES AND INHIBITORS | AVILA THERAPEUTICS, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011034741-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | GRUENENTHAL GMBH (DE) | 2010-09-30 | — | — | US | disclosed |
| WO-2010108651-A1 | SUBSTITUTED SPIRO-AMIDE COMPOUNDS | Grünenthal GmbH (DE) | 2010-09-30 | — | — | WO | disclosed |
| EP-2215085-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2009053737-A2 | PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | WO | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269298-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | EGFR, BLK, CSNK1A1L | USP2 4695/4885SMN1; SMN2 4694/4885ALDH1A1 4631/4885 |
| US-20250136611-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE | VHL, BRCA1, TP53 | USP2 3195/4885SMN1; SMN2 1670/4885ALDH1A1 246/4885 |
| US-20240254115-A1 | New Pyridine-Sulfonamide Derivatives as Sigma Ligands | SIGMAR1, TMEM97, OPRD1 | USP2 2065/4885SMN1; SMN2 3118/4885ALDH1A1 1011/4885 |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | USP2 3600/4885SMN1; SMN2 838/4885ALDH1A1 734/4885 |
| US-20100249095-A1 | Substituted Spiro-amide Compounds | BDKRB1, BDKRB2, REN | USP2 4864/4885SMN1; SMN2 3545/4885ALDH1A1 2086/4885 |
| US-20240270739-A1 | Heteroaryl Fluoroalkenes As DGK Inhibitors | DGKA, DGKG, DGKK | USP2 2393/4885SMN1; SMN2 4771/4885ALDH1A1 2923/4885 |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | ADRM1, BRDT, RBX1 | USP2 55/4885SMN1; SMN2 2559/4885ALDH1A1 4038/4885 |
| US-20090118305-A1 | PYRIDINE AND PYRAZINE DERIVATIVES - 083 | MKI67, CCND3, CCND1 | USP2 4497/4885SMN1; SMN2 2234/4885ALDH1A1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.